What is ALS Phase 3 Dexpramipexole Extension Study?

Category: Others

false

NCT01622088 (ENVISION) is an open label, extension study of the EMPOWER trail. The trial will looks at the long term safety and efficacy of dexpramipexole in subjects with amyotrophic lateral sclerosis (ALS). Only patients previously enrolled in EMPOWER are eligible. Other study IDs: 223AS304.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 1
Mild 2
None 4

Commonly reported side effects and conditions associated with ALS Phase 3 Dexpramipexole Extension Study

Side effect Patients
Headaches 1
Nausea 1
Waking up during the night 1

Why patients stopped taking ALS Phase 3 Dexpramipexole Extension Study

Multiple reasons could be selected

Reason Patients
Course of treatment ended 3
Other 2
Did not seem to work 1
Doctor's advice 1
Expense 1
Side effects too severe 1
See all 6 patients who've stopped using ALS Phase 3 Dexpramipexole Extension Study

Duration

Stopped using ALS Phase 3 Dexpramipexole Extension Study

Duration Patients
Less than 1 month 1
1 - 6 months 4
6 months - 1 year 1
Adherence
Adherence Evaluations
Always 6
Usually 1
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 1
Not at all hard to take 6
Cost per month
Cost per month Evaluations
$200+ 1
$100-199 0
$50-99 0
$25-49 0
< $25 5
Not specified 1
Last updated:
There are no evaluations for ALS Phase 3 Dexpramipexole Extension Study.